Top

International Journal of Clinical Oncology

Published in:

01-10-2014 | Original Article

Five-year potency preservation after iodine-125 prostate brachytherapy

Authors: Shuichi Nishimura, Atsunori Yorozu, Toshio Ohashi, Masanori Sakayori, Yasuto Yagi, Toru Nishiyama, Shiro Saito, Yutaka Shiraishi, Kayo Yoshida, Kazuhito Toya, Naoyuki Shigematsu

Published in: International Journal of Clinical Oncology | Issue 5/2014

Abstract

Background

We aimed to evaluate long-term erectile function following prostate brachytherapy, based on patient characteristics and treatment factors.

Methods

Between 2003 and 2006, 665 men with localized prostate cancer were treated with ¹²⁵I permanent seed implantation. None was given adjuvant hormone therapy. Erectile function was assessed before treatment, and at 6 months, 1, 2, 3, 4 and 5 years after implantation using the Mount Sinai Erectile Function Score (MSEFS) of 0–3 (0 = no erections, 1 = erections insufficient for intercourse, 2 = suboptimal erections but sufficient for intercourse, 3 = normal erectile function). Potency was defined as score 2 or 3, and 382 men were potent before treatment. Univariate and multivariate analyses were performed on the data from these 382 patients to identify variables associated with potency preservation.

Results

In patients who were potent before treatment, the actuarial potency preservation rate fell to 46.2 % at 6 months after brachytherapy, and then slowly recovered reaching 52.0 % at 5 years after brachytherapy. In multivariate logistic regression analysis, patient age (p = 0.04) and pre-treatment MSEFS (p < 0.001) were predictors of 5-year potency preservation. Neoadjuvant hormone therapy affected potency preservation only at 6 months after brachytherapy.

Conclusions

Patient age at implantation and pre-treatment erectile function are predictive factors for the development of erectile dysfunction following prostate brachytherapy.

Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33PubMedCrossRef

Peschel RE, Colberg JW (2003) Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4:233–241PubMedCrossRef

Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261PubMedCrossRef

Robinson JW, Moritz S, Fung T (2002) Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 54:1063–1068PubMedCrossRef

Crook JM, Gomez-Iturriaga A, Wallace K et al (2011) Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 29:362–368PubMedCrossRef

Alemozaffar M, Regan MM, Cooperberg MR et al (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205–1214PubMedCrossRef

Zelefsky MJ, Hollister T, Raben A et al (2000) Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261–1266PubMedCrossRef

Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69:338–342PubMedCrossRef

Merrick GS, Butler WM, Wallner KE et al (2005) Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62:437–447PubMedCrossRef

10.

Cancer Registration Committee of the Japanese Urological A (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61CrossRef

11.

Ohashi T, Yorozu A, Toya K et al (2005) Acute urinary morbidity following I-125 prostate brachytherapy. Int J Clin Oncol 10:262–268PubMedCrossRef

12.

Ohashi T, Yorozu A, Toya K et al (2007) Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry. Jpn J Clin Oncol 37:121–126PubMedCrossRef

13.

Yoshida K, Ohashi T, Yorozu A et al (2013) Comparison of preplanning and intraoperative planning for I-125 prostate brachytherapy. Jpn J Clin Oncol 43:383–389PubMedCrossRef

14.

Stock RG, Stone NN, Cesaretti JA et al (2006) Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64:527–533PubMedCrossRef

15.

Stock RG, Kao J, Stone NN (2001) Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165:436–439PubMedCrossRef

16.

Zagar TM, Stock RG, Cesaretti JA et al (2007) Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 6:26–33PubMedCrossRef

17.

Taira AV, Merrick GS, Galbreath RW et al (2009) Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 75:639–648PubMedCrossRef

18.

Potters L, Torre T, Fearn PA et al (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50:1235–1242PubMedCrossRef

19.

Snyder KM, Stock RG, Buckstein M et al (2012) Long-term potency preservation following brachytherapy for prostate cancer. BJU Int 110:221–225PubMedCrossRef

20.

Kollmeier MA, Fidaleo A, Pei X et al (2013) Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer. BJU Int 111:1231–1236PubMedCrossRef

21.

Zelefsky MJ, McKee AB, Lee H et al (1999) Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 53:775–778PubMedCrossRef

22.

Bannowsky A, Schulze H, van der Horst C et al (2008) Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 101:1279–1283PubMedCrossRef

23.

Pahlajani G, Raina R, Jones JS et al (2010) Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int 106:1524–1527PubMedCrossRef

Title: Five-year potency preservation after iodine-125 prostate brachytherapy
Authors: Shuichi Nishimura
Atsunori Yorozu
Toshio Ohashi
Masanori Sakayori
Yasuto Yagi
Toru Nishiyama
Shiro Saito
Yutaka Shiraishi
Kayo Yoshida
Kazuhito Toya
Naoyuki Shigematsu
Publication date: 01-10-2014
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0632-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy

Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen

Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer

Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan

Radiofrequency ablation for the treatment of recurrent bone and soft-tissue sarcomas in non-surgical candidates

Changing patterns in thyroid cancer incidence and mortality in the Slovak Republic by histological type and age

Keynote webinar | Spotlight on antibody–drug conjugates in cancer